The Effects of Adding TCM-700C on the Standard Combination Treatment for HCV Genotype 1 Patients(Phase III)
Status:
Withdrawn
Trial end date:
2018-06-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double blind, multi-center, placebo controlled, three parallel arms,
Phase IIb/III clinical study to evaluate the effects of adding a TCM-700C with a low or high
dose onto the combination treatment (PegIFN plus RBV) for subjects with naive genotype 1 HCV
infection.
This will be demonstrated by a higher sustained virologic response rate, defined as the
absence of detectable HCV RNA 24 weeks after the termination of combination treatment,
compared with the placebo add-on.